Is PHAT or NERV more profitable?

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -76.77% N/A -44.29% Minerva Neurosciences N/A N/A -32.63%

Does the media refer more to PHAT or NERV?

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 2 articles in the media. Minerva Neurosciences' average media sentiment score of 1.27 beat Phathom Pharmaceuticals' score of 1.24 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NERV or TBPH?

In the previous week, Theravance Biopharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Theravance Biopharma's score of 0.25 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMPH or NERV?

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.36 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPRY or NERV?

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Minerva Neurosciences. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat ARS Pharmaceuticals' score of 0.57 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NERV or ZVRA?

In the previous week, Zevra Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Zevra Therapeutics' score of 0.89 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Minerva Neurosciences (NERV) Competitors

$4.12 -0.15 (-3.40%)

As of 03:48 PM Eastern

Compare

NERV vs. PHAT, TBPH, AMPH, SPRY, and ZVRA

Should you buy Minerva Neurosciences stock or one of its competitors? MarketBeat compares Minerva Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Neurosciences include Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH), ARS Pharmaceuticals (SPRY), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Minerva Neurosciences	N/A	N/A	-32.63%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phathom Pharmaceuticals presently has a consensus target price of $24.50, suggesting a potential upside of 116.24%. Minerva Neurosciences has a consensus target price of $10.50, suggesting a potential upside of 154.55%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 2 articles in the media. Minerva Neurosciences' average media sentiment score of 1.27 beat Phathom Pharmaceuticals' score of 1.24 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.16	-$221.25M	-$2.12	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Phathom Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Theravance Biopharma?

Minerva Neurosciences (NASDAQ:NERV) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Theravance Biopharma has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Theravance Biopharma	$107.46M	8.13	$105.89M	$2.20	7.70

Minerva Neurosciences presently has a consensus price target of $10.50, suggesting a potential upside of 154.55%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 14.52%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has a net margin of 104.34% compared to Minerva Neurosciences' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Theravance Biopharma	104.34%	18.84%	10.94%

Minerva Neurosciences has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

In the previous week, Theravance Biopharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Theravance Biopharma's score of 0.25 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Theravance Biopharma beats Minerva Neurosciences on 11 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Minerva Neurosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Minerva Neurosciences	N/A	N/A	-32.63%

Amphastar Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.27
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.36 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals currently has a consensus price target of $22.00, indicating a potential upside of 17.55%. Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 154.55%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amphastar Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Minerva Neurosciences on 11 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

ARS Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	8.97	-$171.30M	-$2.01	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Minerva Neurosciences. MarketBeat recorded 8 mentions for ARS Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat ARS Pharmaceuticals' score of 0.57 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Minerva Neurosciences has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Minerva Neurosciences' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Minerva Neurosciences	N/A	N/A	-32.63%

ARS Pharmaceuticals currently has a consensus target price of $28.20, indicating a potential upside of 270.37%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 154.55%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ARS Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, indicating that its stock price is 116% less volatile than the broader market.

Summary

ARS Pharmaceuticals beats Minerva Neurosciences on 10 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Zevra Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Minerva Neurosciences presently has a consensus price target of $10.50, indicating a potential upside of 154.55%. Zevra Therapeutics has a consensus price target of $29.29, indicating a potential upside of 121.69%. Given Minerva Neurosciences' higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Zevra Therapeutics has a net margin of 101.58% compared to Minerva Neurosciences' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Zevra Therapeutics	101.58%	51.49%	28.86%

Minerva Neurosciences has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Zevra Therapeutics	$106.47M	7.34	$83.23M	$1.99	6.64

In the previous week, Zevra Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.27 beat Zevra Therapeutics' score of 0.89 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Zevra Therapeutics beats Minerva Neurosciences on 13 of the 15 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$193.35M	$2.98B	$6.74B	$12.55B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-0.14	18.78	27.01	24.38
Price / Sales	N/A	830.13	585.49	117.90
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	-1.27	4.25	10.85	6.35
Net Income	-$293.42M	$64.26M	$3.58B	$330.89M
7 Day Performance	-13.52%	-3.08%	-2.09%	-0.97%
1 Month Performance	-8.54%	2.66%	3.29%	-0.36%
1 Year Performance	131.74%	20.80%	26.51%	20.00%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	2.4678 of 5 stars	$4.13 -3.4%	$10.50 +154.5%	+146.1%	$193.35M	N/A	N/A	9	Positive News
PHAT Phathom Pharmaceuticals	2.1233 of 5 stars	$11.55 +1.5%	$24.50 +112.1%	+18.8%	$907.62M	$175.11M	N/A	110	News Coverage
TBPH Theravance Biopharma	2.7797 of 5 stars	$17.01 +0.1%	$19.40 +14.1%	+49.6%	$876.40M	$107.46M	7.73	110
AMPH Amphastar Pharmaceuticals	3.394 of 5 stars	$20.08 +2.4%	$22.00 +9.6%	-10.9%	$864.66M	$719.89M	12.10	1,976	Gap Up
SPRY ARS Pharmaceuticals	3.2682 of 5 stars	$8.19 -1.7%	$28.20 +244.3%	-56.2%	$827.20M	$84.28M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. PHAT, TBPH, AMPH, SPRY, and ZVRA

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to Theravance Biopharma?

Summary

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to ARS Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. PHAT, TBPH, AMPH, SPRY, and ZVRA

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Is PHAT or NERV more profitable?

Do insiders & institutionals have more ownership in PHAT or NERV?

Do analysts recommend PHAT or NERV?

Does the media refer more to PHAT or NERV?

Which has preferable valuation & earnings, PHAT or NERV?

Which has more volatility & risk, PHAT or NERV?

Summary

How does Minerva Neurosciences compare to Theravance Biopharma?

Do institutionals & insiders hold more shares of NERV or TBPH?

Which has better valuation and earnings, NERV or TBPH?

Do analysts prefer NERV or TBPH?

Is NERV or TBPH more profitable?

Which has more volatility and risk, NERV or TBPH?

Does the media prefer NERV or TBPH?

Summary

How does Minerva Neurosciences compare to Amphastar Pharmaceuticals?

Is AMPH or NERV more profitable?

Which has preferable earnings & valuation, AMPH or NERV?

Do insiders & institutionals have more ownership in AMPH or NERV?

Does the media refer more to AMPH or NERV?

Do analysts rate AMPH or NERV?

Which has more volatility and risk, AMPH or NERV?

Summary

How does Minerva Neurosciences compare to ARS Pharmaceuticals?

Which has better earnings and valuation, SPRY or NERV?

Does the media favor SPRY or NERV?

Do institutionals and insiders believe in SPRY or NERV?

Is SPRY or NERV more profitable?

Do analysts rate SPRY or NERV?

Which has more volatility and risk, SPRY or NERV?

Summary

How does Minerva Neurosciences compare to Zevra Therapeutics?

Do analysts prefer NERV or ZVRA?

Is NERV or ZVRA more profitable?

Which has more volatility and risk, NERV or ZVRA?

Which has better valuation & earnings, NERV or ZVRA?

Does the media prefer NERV or ZVRA?

Do insiders and institutionals believe in NERV or ZVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools